WHO collects statistics on leprosy annually from countries to assess the situation and to publish an annual global leprosy update. In 2021, 143 countries provided statistics, as compared with 127 in 2020.
DownloadA letter to the editor published in the September 2022 issue of Leprosy Review.
Visit siteSingle-dose rifampicin post-exposure prophylaxis (SDR-PEP) is a preventive treatment for leprosy that can be used to reduce the risk of developing leprosy among contacts of leprosy patients and thus, indirectly, reduce transmission of leprosy bacilli. Large-scale, international studies show that SDR-PEP is safe and contributes to reducing leprosy incidence and preventing secondary disabilities. It has been tested in more than 11 countries, and more than 175,000 people have received treatment in research settings. The World Health Organization (WHO) advises the use of SDR-PEP in the Roadmap for Neglected Tropical Diseases 2021 – 2030, the Global Leprosy Strategy, and the WHO Guidelines for the Diagnosis, Treatment, and Prevention of Leprosy. The Global Partnership for Zero Leprosy also recommends SDR-PEP for routine leprosy control services.
ENG ESP FR PORCambodia’s RHM HGTV channel reports on the National Leprosy Programme’s roadmapping and action planning workshops. (23:45 – 27:00)
Visit siteGlobal Partnership for Zero Leprosy Leadership Conference in Brentford, London – 11 June 2022
DownloadGlobal Partnership for Zero Leprosy Leadership Teleconference – 3 March 2022
DownloadThis factsheet distills the key messages and recommendations of the UN Special Rapporteur’s June 2022 report to the UN Human Rights Council. The report calls for a people-centered approach that addresses structural violence and unequal power relations.
DownloadRTI reports on Prime Minister Patrick Achi’s commitment to ending leprosy in Côte d’Ivoire by 2030.
Visit site